Stock listing

SIX Swiss:MRNA.USD Moderna, Inc. Aktie

Swiss listing (SIX Swiss) of Moderna, Inc. · home listing NASDAQ:MRNA

Follow Moderna, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:MRNA

$226.89 USD +8.88 (+4.1%)

Close on Oct 19, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:MRNA

Past year +732.9% · daily closes, Oct 20, 2025 – Oct 19, 2026, adjusted for splits
Day range
$216.00 – $236.77 USDOct 19, 2026
Volume
18.77M sharesOct 19, 2026
Market value
$90.58B USDAt the close on Oct 19, 2026 · price × 399.2M shares outstanding
52-week range
$22.28 – $242.29 USDLowest and highest trades, Oct 20, 2025 – Oct 19, 2026
Moderna, Inc. logo
Ticker
SIX Swiss:MRNA.USD
Asset type
Stock
Exchange
SIX Swiss
Currency
USD

What changed lately

Calls

Replays

  • Moderna (NASDAQ:MRNA) Q2 2026 Earnings Call

    Fri, Jul 31, 2026 · 8:00 AM ET

    Watch Transcript

  • Moderna (NASDAQ:MRNA) Q1 2026 Earnings Call

    Fri, May 01, 2026 · 8:00 AM ET

    Watch Transcript

  • Moderna (NASDAQ:MRNA) Q4 2025 Earnings Call

    Fri, Feb 13, 2026 · 8:00 AM ET

    Watch Transcript

Latest news

Moderna to Report Third Quarter 2026 Financial Results on Friday, November 6, 2026

Oct 13, 2026

Moderna Adds Chief Operating Officer Role as Company Expands into Oncology

Sep 30, 2026

Moderna Announces Late-Breaking Data to be Presented at ESMO Congress 2026

Sep 21, 2026

Moderna to Present at Upcoming Conferences in September 2026

Sep 1, 2026

Moderna Announces Pricing of Upsized $2.6 Billion Offering of Convertible Senior Notes

Aug 28, 2026

Moderna Receives U.S. FDA Approval for Updated 2026-2027 COVID-19 Vaccines

Aug 27, 2026

Moderna Announces Proposed Private Placement of $2.0 Billion of Convertible Senior Notes

Aug 27, 2026

Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA

Aug 5, 2026

Moderna Announces Initiation of Phase 1 Clinical Trial of mRNA-1469, Moderna's Investigational Vaccine Against Bundibugyo Ebolavirus

Aug 4, 2026

Moderna Reports Second Quarter 2026 Financial Results and Provides Business Updates

Jul 31, 2026

All Moderna, Inc. news

Financings

  • 0.00% Convertible Senior Notes due 2032

    Aug 28, 2026

    Made bigger: US$2.6B

    Use of proceeds: Pay about $285.0 million for capped call transactions and general corporate purposes, possibly including growing the oncology business and repaying debt

    Announced Aug 27, 2026 · Made bigger Aug 28, 2026

Read by 6ix AI from the company's releases

Decks

Moderna, Inc. on 6ix

News releases
58 in the last 12 months · 389 in all · newest Oct 13, 2026 · oldest 2021
Calls
25 calls with a replay · 25 with a transcript · latest Jul 31, 2026
Decks
62 decks · latest Jul 31, 2026

Where Moderna, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:MRNA · Home listingNASDAQUnited StatesUSD
gettex:0QFgettexGermanyEUR
Milan:1MRNAMilanItalyEUR
Xetra:0QFXetraGermanyEUR
Tradegate:0QFTradegateGermanyEUR
BCBA:MRNABCBAArgentinaARS
LS Exchange:A2N9D9LS ExchangeGermanyEUR
BMV:MRNABMVMexicoMXN
B3:M1RN34B3BrazilBRL
BOATS:MRNABOATSUnited StatesUSD
EUROTLX:4MRNAEUROTLXItalyEUR
Lang & Schwarz:A2N9D9Lang & SchwarzGermanyEUR
LSIN:0A45LSINUnited KingdomUSD
BIVA:MRNABIVAMexicoMXN
BCBA:MRNADBCBAArgentinaUSD
Stuttgart:0QFStuttgartGermanyEUR
Frankfurt:0QFFrankfurtGermanyEUR
Aquis:0QFDAquisUnited KingdomEUR
SIX Swiss:MRNASIX SwissSwitzerlandCHF
Munich:0QFMunichGermanyEUR
VIE:MRNAViennaAustriaEUR
SIX Swiss:MRNA.USD · This pageSIX SwissSwitzerlandUSD
BCBA:MRNACBCBAArgentinaUSD
Dusseldorf:0QFDusseldorfGermanyEUR
BX Swiss:0QFBX SwissSwitzerlandCHF
Hamburg:0QFHamburgGermanyEUR
BSESOF:0QFBSESOFBulgariaEUR
BVL:MRNAUSBVLPeruPEN
Hanover:0QFHanoverGermanyEUR
Turquoise:MRNANTurquoiseUnited KingdomUSD
Aquis:0QFDAquisUnited KingdomEUR
BCBA:MRNA.CIBCBAArgentinaARS

Log in to ask 6ix AI your own questions about Moderna, Inc.